Listed Indian arm of AstraZeneca plc selling branded oncology, diabetes and respiratory drugs in India.
Listed Indian arm of AstraZeneca plc selling branded oncology, diabetes and respiratory drugs in India.
Markets its parent's patented medicines in India rather than discovering most of them itself, so launches depend on regulatory approvals and on what the parent chooses to bring to the Indian market. AstraZeneca plc holds a majority stake.
In one line: AstraZeneca's Indian pharma subsidiary.
Moat: narrow (brand, IP / patents). Access to AstraZeneca's global oncology and specialty pipeline, though the Indian entity is a small local unit.
Headquarters: Bengaluru, India · Founded: 1979 · Employees: 760
Size AstraZeneca Pharma India (ASTRAZEN.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.62B, the 445th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹6,044 on 18 Nov 2026.
Performance Over six months the shares fell 30.5%, against -3.7% for the median peer and +3.8% for the India market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue grew 29.7% over the last twelve months (peer median +6.6%); the operating margin is 9.9% (peer median 12.0%).
Valuation It trades at 5.6× enterprise value to sales against a peer median of 4.5× (9th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 42% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 34.2 points above its cost of capital (14.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹26.0B | ₹22.8B | ₹17.2B | ₹13.0B | ₹10.0B |
| Revenue growth | — | +33% | +32% | +29% | — |
| Gross profit | ₹6.42B | ₹5.94B | ₹4.43B | ₹4.32B | ₹3.55B |
| EBITDA | ₹2.78B | ₹2.66B | ₹2.58B | ₹1.87B | ₹1.67B |
| Net income | ₹1.78B | ₹1.88B | ₹1.16B | ₹1.62B | ₹993M |
| Free cash flow | n/a | ₹32.1M | ₹954M | ₹492M | ₹729M |
| Capital expenditure | n/a | ₹36.1M | ₹17.5M | ₹108M | ₹85.2M |
| Total debt | ₹962M | ₹1.11B | ₹357M | ₹45.9M | ₹72.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| AstraZeneca Pharma India ASTRAZEN.NS | $1.62B | -30% | +30% | 10% | 5.6× | 42.4% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | $4.79B | +10% | +12% | 33% | 10.2× | 26.4% |
| Novartis India NOVARTIND.NS | n/a | +67% | n/a | n/a | n/a | n/a |
| Pfizer PFIZER.NS | $1.88B | -20% | +12% | 34% | 5.5× | 11.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ASTRAZEN.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.1% | -3.9% | 6th highest of 21 |
| 6-month return | -30.5% | -3.7% | 5th lowest of 20 |
| Distance from 52-week high | -36.2% | -33.8% | 11th highest of 21 |
| Revenue growth (TTM) | +29.7% | +6.6% | 3rd highest of 20 |
| Operating margin | 9.9% | 12.0% | 10th lowest of 20 |
| EV / Sales | 5.6× | 4.5× | 9th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 42.4% | 11.3% | most demanding of 16 |
| Growth delivered (Del g) | +23.0% | +6.8% | 3rd highest of 16 |
| Hurdle (Req g minus delivered) | +19.5 pp | +7.6 pp | 6th most demanding of 16 |
| ROIC minus cost of capital | +34.2 pp | -1.0 pp | 2nd highest of 21 |
| EV / EBITDA | 52.6× | 17.1× | most expensive of 7 |
| Net debt / EBITDA | -1.7× | 1.9× | 2nd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | 5.6× | 42.4% | +23.0% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | 12.2× | 33.0% | +0.9% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 7.2× | n/a | n/a |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 9.8× | 31.1% | -15.1% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 5.2× | 12.8% | -14.0% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 1.2× | -6.6% | -5.6% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 2.0× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 4.5× | 6.0% | -4.3% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 2.2× | -14.9% | +13.5% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 2.5× | n/a | n/a |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 8.9× | 18.4% | +10.8% |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | 0.9× | -6.8% | +32.4% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 3.6× | 31.4% | +29.4% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 2.3× | -3.5% | +6.8% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 6.3× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 16.7× | 11.3% | -11.0% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 2.6× | 3.7% | +9.9% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | 68.8× | n/a | n/a |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 9.7× | 35.3% | +9.2% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 1.4× | -6.1% | +1.9% |